Table 3. comparative studies of patients with gastric cancer ± peritoneal metastasis treated with surgery ± hyperthermic intraperitoneal chemotherapy (HIPEC).
| Author | Year | Trial | Inclusion Criteria | Total Number of patients | Nr. of patients HIPEC | Survival | Nr. of patients Control | Survival | P value |
|---|---|---|---|---|---|---|---|---|---|
| Gastric cancer without peritoneal metastasis | |||||||||
| Koga | 1988 | RCT | cT4 | 47 | 26 | Median OS: 30 months: 83% | 21 | Median OS: 30 months: 67.3% | n.s. |
| Kaibara | 1989 | RCT | cT4 | 82 | 42 | 5-year: 71.5% | 40 | 5-year: 59.7% | n.a. |
| Hamazoe | 1994 | RCT | cT4 | 82 | 42 | 5-year: 64.3% | 40 | 5-year: 52.5% | n.s. |
| Ikeguchi | 1995 | RCT | cT3 | 174 | 78 | Median DFS: 30 months | 96 | Median DFS: 23 months | n.a. |
| Fujimoto | 1999 | RCT | cT4 | 141 | 71 | 2-, 4-, 8-year: 88%, 76%, 62% | 70 | 2-, 4-, 8-year: 77%, 58%, 49% | 0.0362 |
| Yonemura | 2001 | RCT | cT3–T4 | 95 | 48 | 5-year: 61% | 47 | 5-year: 42% | n.a.; RR 0.69 [0.45, 1.06] |
| Cui | 2014 | RCT | cT4 | 192 | 96 | 1-, 3-year: 84.5%, 49.3% | 96 | 1-, 3- year: 79%, 25% | 0.002 |
| Koga | 1988 | NRCT | cT4 | 93 | 38 | 3-year: 73.7% | 55 | 3-year: 52.7% | <0.04 |
| Yonemura | 1995 | NRCT | cT4 | 160 | 79 | 5-year: ≈ 48% | 81 | 5-year: ≈ 35% | 0.052 |
| Hirose | 1999 | NRCT | cT4 | 55 | 15 | Median OS: 33 [7–59] months | 40 | Median OS: 22 [18–26] months | 0.0142 |
| Kunisaki | 2002 | NRCT | cT4 | 124 | 45 | 5-year: 51% | 79 | 5-year: 61% | n.s. |
| Zhu | 2006 | NRCT | cT3-T4 | 118 | 42 | 2-, 4-, 6-year: 83.0%, 70.5%, 67.9% | 54 | 2-, 4-, 6- year: 63.7%, 52.1%, 37.7% | 0.0143 |
| Kang | 2013 | NRCT | cT4 | 112 | 29 | 5-year: 43.9% | 83 | 5-year: 10.7% | 0.029 |
| Gastric cancer with peritoneal metastasis | |||||||||
| Yang | 2011 | RCT | PM | 68 | 34 | Median OS: 11.0 months | 34 | Median OS: 6.5 months | 0.046 |
| Rudloff | 2014 | RCT | PM | 17 | 9 | Median OS: 11.3 months | 8 | Median OS: 4.3 months | n.s. |
| Fujimoto | 1997 | NRCT | PM | 66 | 48 | 1-, 3-, 5-, 8- year: 54.0%, 41.5%, 31.0%, 25.4% | 18 | Median OS: 8.1 months | 0.00167 |
| Kunisaki | 2006 | NRCT | PM | 73 | 21 | n.a. | 52 | n.a. | |
| Li | 2010 | NRCT | PM | 54 | 10 | Median OS: 11.8 months | 44 | Median OS: 6.0 months | <0.001 |
| Zhibing | 2013 | NRCT | PM | 101 | 52 | Median OS: 7.5 months | 49 | Median OS: 6.7 months | n.s. |
| Bonnot | 2019 | NRCT | PM | 277 | 180 | Median OS: 18.6 months | 97 | Median OS: 11.4 months | 0.002 |
RCT, randomized controlled trial; NRCT, non-randomized controlled trial; n.a., not available; n.s., not significant; OS, overall survival; DFS, disease free survival; PM, peritoneal metastasis.